GlassScriptPhysician profile
Trisha Lynn Davis
NPI 1881378172
$5,812.60
in general payments reported to CMS, 2019-2025
31 companies · $80.35 in 2025
The $80.35 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $2,134 · 2024: $3,598 · 2025: $80.35.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,560 · Education: $253.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,559.73 |
| Education | $252.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $995.61 | 2023-2024 | Airsupra, Tezspire, Breztri |
| Genzyme Corporation | $758.39 | 2023-2024 | |
| Glaxosmithkline, LLC. | $499.39 | 2023-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Actelion Pharmaceuticals US, INC. | $475.16 | 2023-2024 | Opsumit, Uptravi |
| United Therapeutics Corporation | $395.95 | 2023-2024 | Tyvaso |
| Regeneron Healthcare Solutions, INC. | $328.03 | 2023-2024 | Dupixent |
| Mylan Specialty L.P. | $267.87 | 2023-2024 | Yupelri |
| Harmony Biosciences LLC | $227.45 | 2023-2024 | Wakix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $206.68 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $200.74 | 2023-2025 | Recarbrio, Zerbaxa, Winrevair |
| Sanofi-Aventis U.S. LLC | $157.43 | 2023-2024 | |
| Genentech USA, INC. | $141.36 | 2023-2024 | Xolair |
| Jazz Pharmaceuticals INC. | $137.33 | 2024 | |
| Amgen INC. | $133.76 | 2023-2024 | Tezspire |
| Mallinckrodt Hospital Products INC. | $130.70 | 2023-2024 | Acthar |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $116.34 | 2023-2024 | Nuzyra |
| Electromed, INC. | $100.73 | 2023-2024 | Smartvest |
| Axsome Therapeutics, INC. | $92.75 | 2024 | Sunosi |
| Pulmonx Corporation | $81.90 | 2023-2024 | Zephyr Endobronchial Valve, Chartis Catheter, Zephyr Delivery Catheter |
| Novartis Pharmaceuticals Corporation | $63.22 | 2023-2024 | |
| Baxter Healthcare | $52.54 | 2024 | Hillrom - Vest System Model 105 Home Care |
| Philips North America LLC | $46.15 | 2023-2024 | (Di7) Home Pi Undivided |
| Inspire Medical Systems, INC. | $38.28 | 2024 | Inspire |
| Pfizer INC. | $23.74 | 2025 | |
| Grifols USA, LLC | $23.00 | 2024 | Prolastin-C Liquid |
| Avadel Cns Pharmaceuticals, LLC | $22.63 | 2023 | Lumryz |
| Ani Pharmaceuticals, INC. | $21.94 | 2023 | Purified Cortrophin Gel |
| Inogen, INC. | $20.48 | 2024 | |
| Phadia US INC. | $19.44 | 2023 | Immunocap |
| Renalytix Ai, INC. | $17.57 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Idorsia Pharmaceuticals US INC | $16.04 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Trisha Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.